(Q42537043)

1 November 2017

title

Severe anemia following combined alpha-interferon/ribavirin therapy of chronic hepatitis C. (English)

1 reference

1 November 2017

1 reference

1 reference

Tappero G

1

1 reference

1 November 2017

Ballaré M

series ordinal

2

1 reference

1 November 2017

Farina M

series ordinal

3

1 reference

1 November 2017

Negro F

series ordinal

4

1 reference

1 November 2017

publication date

1 December 1998

1 reference

1 November 2017

published in

Journal of Hepatology

1 reference

1 November 2017

volume

29

1 reference

1 November 2017

issue

6

1 reference

1 November 2017

page(s)

1033-1034

1 reference

Molecular mechanisms of action of ribavirin

1 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980138-4

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980138-4

7 January 2021

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980138-4

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980138-4

7 January 2021

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980138-4

7 January 2021

The possible involvement of interferons in acquired pure red cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980138-4

7 January 2021

10.1016/S0168-8278(98)80138-4

Identifiers

DOI

1 reference

1 November 2017

1 reference